Concert Pharmaceuticals to Participate in Fireside Chat at the Jefferies London Healthcare Conference

11/9/22 7:00:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $CNCE alert in real time by email

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that it will participate in a fireside chat at the Jefferies London Healthcare Conference on November 16, 2022, at 10:20 a.m. GMT.

A webcast of the presentation may be accessed in the Investors section of the Company's website at www.concertpharma.com. A replay will be available on Concert's website for two weeks following the presentation.

About Concert

Concert Pharmaceuticals is a late-stage clinical biopharmaceutical company that is developing deuruxolitinib (CTP-543), a novel, deuterated, oral JAK1/2 inhibitor. Concert has successfully completed two Phase 3 trials with deuruxolitinib in adults with alopecia areata, a serious autoimmune dermatological disease. The Company is also evaluating the use of deuruxolitinib in other indications and assessing a number of earlier-stage pipeline candidates. For more information, please visit www.concertpharma.com or follow us on Twitter, Instagram or LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221109005071/en/

Get the next $CNCE alert in real time by email

Concert Pharmaceuticals to Participate in Fireside Chat at the Jefferies London Healthcare Conference

Chat with this insight

Recent Analyst Ratings for
$CNCE

$CNCE
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4: Stuart Nancy sold $50,380 worth of shares (6,048 units at $8.33) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 262,596 units (withholding obligation)

SEC Form 4: Munsie Jeffrey A sold $31,375 worth of shares (3,762 units at $8.34) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 88,049 units to cover withholding tax

SEC Form 4: Cassella James V sold $31,375 worth of shares (3,762 units at $8.34) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 173,061 units to satisfy withholding obligation

Concert Pharmaceuticals to Participate in Fireside Chat at the Jefferies London Healthcare Conference

Chat with this insight

Recent Analyst Ratings for $CNCE

$CNCE Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4: Stuart Nancy sold $50,380 worth of shares (6,048 units at $8.33) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 262,596 units (withholding obligation)

SEC Form 4: Munsie Jeffrey A sold $31,375 worth of shares (3,762 units at $8.34) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 88,049 units to cover withholding tax

SEC Form 4: Cassella James V sold $31,375 worth of shares (3,762 units at $8.34) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 173,061 units to satisfy withholding obligation

Recent Analyst Ratings for
$CNCE

$CNCE
Insider Trading